with Design Therapeutics on their DT‑216 Program in FA
FARA and Design Therapeutics will host an informational Q&A session on the DT-216 Program in FA, on Wednesday, January 18, 2023 at 12pm (ET), for the FA patient community. The session will be a Q&A between FARA Ambassador & Board Director, Alex Fielding and Design Therapeutics President and Chief Executive Officer, Dr. Joao Siffert; and the Q&A will be moderated by FARA Director of Patient Engagement, Layne Rodden.
This session will provide information on the DT-216 program, including a review of the recently announced data from the single ascending dose portion of the Phase 1 trial as well as next steps for the Phase 1 trial and the program overall. To read the recent press release from Design Therapeutics, click HERE. Please submit your questions in advance with your registration for the event. Register HERE for the session. Submit your questions HERE. After registering, you will receive a confirmation email with the link to join us. Anyone considering participating in a clinical trial should discuss the matter with his or her physician. FARA does not endorse or recommend any particular studies.